These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38954834)

  • 21. Integrin-α9 overexpression underlies the niche-independent maintenance of leukemia stem cells in acute myeloid leukemia.
    Niibori-Nambu A; Wang CQ; Chin DWL; Chooi JY; Hosoi H; Sonoki T; Tham CY; Nah GSS; Cirovic B; Tan DQ; Takizawa H; Sashida G; Goh Y; Tng J; Fam WN; Fullwood MJ; Suda T; Yang H; Tergaonkar V; Taniuchi I; Li S; Chng WJ; Osato M
    Gene; 2024 Nov; 928():148761. PubMed ID: 39002785
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker.
    Jan M; Chao MP; Cha AC; Alizadeh AA; Gentles AJ; Weissman IL; Majeti R
    Proc Natl Acad Sci U S A; 2011 Mar; 108(12):5009-14. PubMed ID: 21383193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PBX3 is essential for leukemia stem cell maintenance in MLL-rearranged leukemia.
    Guo H; Chu Y; Wang L; Chen X; Chen Y; Cheng H; Zhang L; Zhou Y; Yang FC; Cheng T; Xu M; Zhang X; Zhou J; Yuan W
    Int J Cancer; 2017 Jul; 141(2):324-335. PubMed ID: 28411381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. All-trans retinoic acid enhances, and a pan-RAR antagonist counteracts, the stem cell promoting activity of EVI1 in acute myeloid leukemia.
    Nguyen CH; Bauer K; Hackl H; Schlerka A; Koller E; Hladik A; Stoiber D; Zuber J; Staber PB; Hoelbl-Kovacic A; Purton LE; Grebien F; Wieser R
    Cell Death Dis; 2019 Dec; 10(12):944. PubMed ID: 31822659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analyzing normal and disrupted leukemic stem cell adhesion to bone marrow stromal cells by single-molecule tracking nanoscopy.
    Gorshkova O; Cappaï J; Maillot L; Sergé A
    J Cell Sci; 2021 Sep; 134(18):. PubMed ID: 34435622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between CD34/CD38 and side population (SP) defined leukemia stem cell compartments in acute myeloid leukemia.
    Moshaver B; Wouters RF; Kelder A; Ossenkoppele GJ; Westra GAH; Kwidama Z; Rutten AR; Kaspers GJL; Zweegman S; Cloos J; Schuurhuis GJ
    Leuk Res; 2019 Jun; 81():27-34. PubMed ID: 31002948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imaging Flow Cytometry and Convolutional Neural Network-Based Classification Enable Discrimination of Hematopoietic and Leukemic Stem Cells in Acute Myeloid Leukemia.
    Hybel TE; Jensen SH; Rodrigues MA; Hybel TE; Pedersen MN; Qvick SH; Enemark MH; Bill M; Rosenberg CA; Ludvigsen M
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928171
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GPR84 sustains aberrant β-catenin signaling in leukemic stem cells for maintenance of MLL leukemogenesis.
    Dietrich PA; Yang C; Leung HH; Lynch JR; Gonzales E; Liu B; Haber M; Norris MD; Wang J; Wang JY
    Blood; 2014 Nov; 124(22):3284-94. PubMed ID: 25293777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia.
    Laverdière I; Boileau M; Neumann AL; Frison H; Mitchell A; Ng SWK; Wang JCY; Minden MD; Eppert K
    Blood Cancer J; 2018 Jun; 8(6):52. PubMed ID: 29921955
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduced protocadherin17 expression in leukemia stem cells: the clinical and biological effect in acute myeloid leukemia.
    Xu ZJ; Ma JC; Zhou JD; Wen XM; Yao DM; Zhang W; Ji RB; Wu DH; Tang LJ; Deng ZQ; Qian J; Lin J
    J Transl Med; 2019 Mar; 17(1):102. PubMed ID: 30922328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia.
    de Figueiredo-Pontes LL; Pintão MC; Oliveira LC; Dalmazzo LF; Jácomo RH; Garcia AB; Falcão RP; Rego EM
    Cytometry B Clin Cytom; 2008 May; 74(3):163-8. PubMed ID: 18200595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Leukemic stem cell signatures in Acute myeloid leukemia- targeting the Guardians with novel approaches.
    Thakral D; Gupta R; Khan A
    Stem Cell Rev Rep; 2022 Jun; 18(5):1756-1773. PubMed ID: 35412219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity.
    Williams MS; Basma NJ; Amaral FMR; Wiseman DH; Somervaille TCP
    BMC Cancer; 2021 Oct; 21(1):1153. PubMed ID: 34711181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia.
    Gentles AJ; Plevritis SK; Majeti R; Alizadeh AA
    JAMA; 2010 Dec; 304(24):2706-15. PubMed ID: 21177505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. JAM3 maintains leukemia-initiating cell self-renewal through LRP5/AKT/β-catenin/CCND1 signaling.
    Zhang Y; Xia F; Liu X; Yu Z; Xie L; Liu L; Chen C; Jiang H; Hao X; He X; Zhang F; Gu H; Zhu J; Bai H; Zhang CC; Chen GQ; Zheng J
    J Clin Invest; 2018 May; 128(5):1737-1751. PubMed ID: 29584620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hematopoietic versus leukemic stem cell quiescence: Challenges and therapeutic opportunities.
    O'Reilly E; Zeinabad HA; Szegezdi E
    Blood Rev; 2021 Nov; 50():100850. PubMed ID: 34049731
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemia.
    Diffner E; Beck D; Gudgin E; Thoms JA; Knezevic K; Pridans C; Foster S; Goode D; Lim WK; Boelen L; Metzeler KH; Micklem G; Bohlander SK; Buske C; Burnett A; Ottersbach K; Vassiliou GS; Olivier J; Wong JW; Göttgens B; Huntly BJ; Pimanda JE
    Blood; 2013 Mar; 121(12):2289-300. PubMed ID: 23327922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Attenuation of microRNA-126 expression that drives CD34+38- stem/progenitor cells in acute myeloid leukemia leads to tumor eradication.
    de Leeuw DC; Denkers F; Olthof MC; Rutten AP; Pouwels W; Schuurhuis GJ; Ossenkoppele GJ; Smit L
    Cancer Res; 2014 Apr; 74(7):2094-105. PubMed ID: 24477595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tespa1 facilitates hematopoietic and leukemic stem cell maintenance by restricting c-Myc degradation.
    Lu Y; Yang L; Shen M; Zhang Z; Wang S; Chen F; Chen N; Xu Y; Zeng H; Chen M; Chen S; Wang F; Hu M; Wang J
    Leukemia; 2023 May; 37(5):1039-1047. PubMed ID: 36997676
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bortezomib suppresses self-renewal and leukemogenesis of leukemia stem cell by NF-ĸB-dependent inhibition of CDK6 in MLL-rearranged myeloid leukemia.
    Zhou B; Qin Y; Zhou J; Ruan J; Xiong F; Dong J; Huang X; Yu Z; Gao S
    J Cell Mol Med; 2021 Mar; 25(6):3124-3135. PubMed ID: 33599085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.